# A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

> **NCT05810038** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 787 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05810038
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-15
- **Primary completion:** 2025-08-25
- **Final completion:** 2025-12-10
- **Target enrollment:** 787 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05810038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05810038, "A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05810038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*